Elevated expression of CST1 promotes breast cancer progression and predicts a poor prognosis
| Autor: | Tian Liang Xia, Mu Sheng Zeng, Yong Du, Shi xun Lu, Ning Xue, Zhi ping Zhao, Bo Chen, Da nian Dai, Ai Jun Zhou, Shi Bing Li, Qian Zhong, Yan Li, Wei dong Wei |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
CA15-3 Proteases Messenger RNA Gene knockdown Prognostic biomarker business.industry CST1 medicine.disease Molecular medicine 03 medical and health sciences Breast cancer 030104 developmental biology 0302 clinical medicine Downregulation and upregulation 030220 oncology & carcinogenesis Drug Discovery medicine Cancer research Molecular Medicine Original Article Cystatin business Genetics (clinical) |
| Zdroj: | Journal of Molecular Medicine (Berlin, Germany) |
| ISSN: | 1432-1440 0946-2716 |
| Popis: | Abstract Cystatin SN (CST1) belongs to the type 2 cystatin (CST) superfamily, which restricts the proteolytic activities of cysteine proteases. CST1 has been recently considered to be involved in the development of several human cancers. However, the prognostic significance and function of CST1 in breast cancer remains unknown. In the current study, we found that CST1 was generally upregulated in breast cancer at both mRNA and protein level. Furthermore, overall survival (OS) and disease-free survival (DFS) in the low CST1 expression subgroup were significantly superior to the high CST1 expression subgroup (OS, p p Key messages High CST1 expression is negatively correlated with survival of breast cancer patients. CST1 promotes cell proliferation, clone formation, and metastasis in breast cancer cells. CST1 is a novel potential prognostic biomarker and therapeutic target for breast cancer. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink